We are thrilled to announce Scott Aladeen as the new President of PharMEDium.
Scott joins PharMEDium from his most recent role as the Vice President and Site Head at Avara
Pharmaceutical Services, where he led Avara’s transformation from internal supplier to
customer-facing contract development and manufacturing organization (CDMO). Prior to joining
Avara, Scott spent 15 years as the President of Astellas U.S. Technologies, Inc., where he led
the manufacturing and supply operations.
An expert at aligning strategy, culture, and operational resources, Scott has more than 30 years
of experience in manufacturing, supply chain management, quality assurance and product
Along with this news, we know that you may have heard that PharMEDium recently announced
a new organizational structure aligned to the changing needs of our business.
There has been a reduction in force, and we wanted to provide you an update directly to ensure
you know that our priority remains to become fully operational to serve your compounding
needs as soon as possible; and also to note that we are deeply committed to being the premier
503B sterile compounding company and undisputed leader in quality in the industry. This
change does not impact our ability to provide current service offerings or service levels.
We believe we are on the right path and continue to make progress toward the standards set
under the FDA’s latest guidance, and we have a responsibility to manage our business so we
can continue to make the right investments that expedite our remediation efforts.
On our path to full remediation, we will continue to invest in high-impact projects that create
value for our business and our customer partners, focusing on those efforts that propel our
immediate progress and directly impact our business. We are committed to focusing on
enhanced quality assurance and quality control programs that deliver the highest-quality
products for our customers, and look forward to continuing this charge under Scott’s leadership.